Interaction between the Adhesion Receptor, CD44, and the Oncogene Product, p185 HER2 , Promotes Human Ovarian Tumor Cell Activation*
暂无分享,去创建一个
M. Hung | L. Bourguignon | Hongbo Zhu | A. Chu | N. Iida | Lisha Zhang
[1] B. Toole,et al. Hyaluronan-binding protein in endothelial cell morphogenesis , 1992, Journal of Cell Biology.
[2] J. Niloff,et al. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. , 1993, Cancer research.
[3] M. Sy,et al. A cysteine residue located in the transmembrane domain of CD44 is important in binding of CD44 to hyaluronic acid , 1996, The Journal of experimental medicine.
[4] L. Bourguignon,et al. Ankyrin-binding domain of CD44(GP85) is required for the expression of hyaluronic acid-mediated adhesion function , 1994, The Journal of cell biology.
[5] N. Maihle,et al. Ligand-independent dimerization of oncogenic v-erbB products involves covalent interactions , 1996, Journal of virology.
[6] P. Kincade,et al. CD44 and its interaction with extracellular matrix. , 1993, Advances in immunology.
[7] X. Chen,et al. Hyaluronic acid-induced lymphocyte signal transduction and HA receptor (GP85/CD44)-cytoskeleton interaction. , 1993, Journal of immunology.
[8] William,et al. Characterization of the class III collagen receptor, a phosphorylated, transmembrane glycoprotein expressed in nucleated human cells. , 1988, The Journal of biological chemistry.
[9] N Iida,et al. The Cell Adhesion Molecule, GP116, Is a New CD44 Variant (ex14/v10) Involved in Hyaluronic Acid Binding and Endothelial Cell Proliferation* , 1996, The Journal of Biological Chemistry.
[10] P. Herrlich,et al. CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. , 1991, Cancer research.
[11] M. Hung,et al. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[12] Cori Bargmann,et al. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185 , 1986, Cell.
[13] L. Bourguignon,et al. Post-translational protein modification and expression of ankyrin-binding site(s) in GP85 (Pgp-1/CD44) and its biosynthetic precursors during T-lymphoma membrane biosynthesis. , 1991, The Journal of biological chemistry.
[14] S. Ethier,et al. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[15] L. Liotta,et al. Reduced Nm23/Awd protein in tumour metastasis and aberrant Drosophila development , 1989, Nature.
[16] L. Bourguignon,et al. Acylation of the lymphoma transmembrane glycoprotein, GP85, may be required for GP85-ankyrin interaction. , 1991, Journal of Biological Chemistry.
[17] L. Bourguignon,et al. The lymphoma transmembrane glycoprotein GP85 (CD44) is a novel guanine nucleotide-binding protein which regulates GP85 (CD44)-ankyrin interaction. , 1992, The Journal of biological chemistry.
[18] M. Hung,et al. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. , 1993, Cancer research.
[19] L. Bourguignon,et al. New CD44 splice variants associated with human breast cancers , 1995, Journal of cellular physiology.
[20] C. Underhill,et al. CD44: the hyaluronan receptor. , 1992, Journal of cell science.
[21] R. Bast,et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. , 1990, Cancer research.
[22] G. Nicolson,et al. Mechanisms of c-erbB2/neu oncogene-induced metastasis and repression of metastatic properties by adenovirus 5 E1A gene products. , 1992, Oncogene.
[23] L. Ellis,et al. Expression of CD44R1 adhesion molecule in colon carcinomas and metastases , 1993, The Lancet.
[24] Y. Yarden,et al. Neu and its ligands: From an oncogene to neural factors , 1993, BioEssays : news and reviews in molecular, cellular and developmental biology.
[25] S. Jalkanen,et al. Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin , 1992, The Journal of cell biology.
[26] L. Bourguignon,et al. Overexpression of CD44 in pl85(neu)-transfected NIH3T3 cells promotes an up-regulation of hyaluronic acid-mediated membrane-cytoskeleton interaction and cell adhesion. , 1996, Oncogene.
[27] M. Hung,et al. Aberrant expression of the c-erbB-2/neu protooncogene in ovarian cancer. , 1992, Cancer letters.
[28] B. Pauli,et al. Tumor invasion: a consequence of destructive and compositional matrix alterations. , 1988, Human pathology.
[29] L. Bourguignon,et al. Lymphoma protein kinase C is associated with the transmembrane glycoprotein, GP85, and may function in GP85-ankyrin binding. , 1989, The Journal of biological chemistry.
[30] L. Bourguignon. Chapter 14 Interactions between the Membrane-Cytoskeleton and CD44 during Lymphocyte Signal Transduction and Cell Adhesion , 1996 .
[31] J. Niloff,et al. Functional heterogeneity of CD44 molecules in ovarian cancer cell lines. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] H. Liao,et al. N-terminal and central regions of the human CD44 extracellular domain participate in cell surface hyaluronan binding. , 1995, Journal of immunology.
[33] J. Bell,et al. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[34] M. Piver,et al. Epidemiology and etiology of ovarian cancer. , 1991, Seminars in oncology.